Sino Biopharmaceutical (1177) AI Stock Analysis

• Market Cap: $150.05B
• Dividend Yield: 1.01%
• Average Volume (3M): 174.09M
• Price to Earnings (P/E): 38.7
• Beta (1Y): 1.15
• Revenue Growth: 13.69%
• EPS Growth: 50.71%
• Country: HK
• Employees: 24,379
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): 0.21
• Shares Outstanding: 18,760,717,000
• 10 Day Avg. Volume: 149,954,684
• 30 Day Avg. Volume: 174,086,697
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 3.46
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: 16.29
• 1Y Price Target: $8.97
• Price Target Upside: 0.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 68 Neutral
• Price Target: HK$7.50 ▼(-15.82% Downside)

Sino Biopharmaceutical's strong technical momentum is the most significant factor boosting its score, reflecting positive market sentiment. Financial performance is solid but needs improvement in revenue growth and cash flow transparency. Valuation concerns due to a high P/E ratio and moderate dividend yield act as a constraint on the overall score.

Sino Biopharmaceutical Business Overview & Revenue Model

Company Description

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

How the Company Makes Money

Sino Biopharmaceutical generates revenue primarily through the sale of its pharmaceutical products across various therapeutic areas. The company's revenue streams include sales from both innovative drugs and generic medicines, particularly in areas such as oncology, cardiovascular, and respiratory diseases. A significant portion of its earnings is driven by its robust distribution network and strategic partnerships within the healthcare industry. The company also invests heavily in research and development to create new drugs and improve existing ones, which helps to maintain a competitive edge and drive long-term growth. Collaborations with international pharmaceutical companies and research institutions further enhance its product offerings and market reach.

Sino Biopharmaceutical Financial Statement Overview

Summary

Sino Biopharmaceutical shows strong profitability with high gross and net profit margins, and a stable balance sheet. However, concerns over moderate revenue growth and incomplete cash flow data slightly detract from its financial performance.

Income Statement

Sino Biopharmaceutical demonstrated strong gross profit margins and net profit growth over the past year. The gross profit margin stands at a high level, reflecting efficient cost management. The net profit margin also improved, showcasing enhanced profitability. However, revenue growth was moderate, indicating room for improvement in expanding sales.

Balance Sheet

The company maintains a healthy balance sheet with a reasonable debt-to-equity ratio, indicating prudent leverage. Return on Equity (ROE) shows positive returns, although room for optimization exists. The equity ratio remains solid, reflecting a stable capital structure, though the increasing debt might warrant caution.

Cash Flow

Cash flow metrics present a mixed picture. While the company has generated positive free cash flow historically, there was an absence of operating cash flow data for the latest year, which raises concerns about cash generation capabilities. The free cash flow to net income ratio suggests efficient cash conversion, yet the lack of current data creates uncertainty.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.87B	26.20B	28.78B	26.86B	23.65B
Gross Profit	23.53B	21.21B	22.98B	21.53B	18.46B
EBITDA	6.11B	6.98B	6.69B	19.87B	6.54B
Net Income	3.50B	2.33B	5.00B	14.61B	4.34B
Balance Sheet
Total Assets	65.41B	63.60B	64.06B	60.54B	47.21B
Cash, Cash Equivalents and Short-Term Investments	14.60B	14.12B	16.92B	15.79B	16.43B
Total Debt	9.78B	12.58B	13.98B	12.12B	14.21B
Total Liabilities	22.63B	25.43B	26.12B	22.81B	24.79B
Stockholders Equity	31.96B	30.47B	29.75B	30.29B	16.75B
Cash Flow
Free Cash Flow	5.22B	4.36B	4.56B	3.47B	3.47B
Operating Cash Flow	6.62B	6.07B	6.27B	5.37B	5.33B
Investing Cash Flow	-1.71B	-756.98M	-4.07B	-2.52B	-7.85B
Financing Cash Flow	-6.32B	-6.55B	-3.19B	-3.23B	2.23B

Sino Biopharmaceutical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1177, the sentiment is Positive. The current price of 8.91 is above the 20-day moving average (MA) of 7.89, above the 50-day MA of 7.01, and above the 200-day MA of 4.43, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 62.01 is Neutral, neither overbought nor oversold. The STOCH value of 77.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1177.

Sino Biopharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1177	68 Neutral	$150.05B	38.66	11.72%	1.01%	13.69%	50.71%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
IVBXF	―	$21.99B	143.23	8.41%	―	―	―
TRSBF	―	$9.41B	31.09	15.34%	0.73%	―	―
WXIBF	―	$18.42B	32.84	9.79%	―	―	―
1877	54 Neutral	HK$45.42B	―	-16.25%	―	44.21%	46.11%
9926	53 Neutral	HK$135.59B	―	-14.40%	―	33.46%	-7.60%

Sino Biopharmaceutical Corporate Events

Sino Biopharmaceutical’s Innovative Cancer Drug TQB3142 Gains NMPA Approval for Clinical Trials

Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3142, a novel PROTAC molecule targeting Bcl-xL protein for the treatment of malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug is designed to induce apoptosis in tumor cells with a reduced risk of platelet toxicity, offering a promising new treatment option in a field where no Bcl-xL inhibitors are currently approved worldwide.

Sino Biopharmaceutical’s TQB3122 IND Application Accepted by NMPA

Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3122, a PARP1 inhibitor designed for treating advanced malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug shows promise due to its high selectivity and ability to penetrate the blood-brain barrier, potentially offering new treatment options for intracranial tumors. The acceptance of this application marks a significant step for the company, as there are currently no approved drugs worldwide targeting the same mechanism, positioning Sino Biopharmaceutical as a potential leader in this niche market.

Sino Biopharmaceutical’s Phase II Trial for Innovative Cancer Drug Approved

Sino Biopharmaceutical Limited has announced that its subsidiary, LaNova Medicines, has received approval from China’s National Medical Products Administration to conduct Phase II clinical trials for LM-24C5, a CEACAM5/4-1BB bispecific antibody. This innovative drug targets CEACAM5-positive advanced solid tumors and shows promise in enhancing anti-tumor activity by redirecting immune cells to the tumor microenvironment. The approval marks a significant step in the company’s efforts to develop a First-in-Class immunotherapy, potentially strengthening its position in the oncology treatment market.

Sino Biopharmaceutical’s Rovadicitinib Gains Breakthrough Designation for cGVHD

Sino Biopharmaceutical announced that its independently developed Rovadicitinib Tablet, a JAK/ROCK inhibitor, has been included in the Breakthrough Therapeutic Designation process by China’s National Medical Products Administration for treating chronic graft-versus-host disease (cGVHD). This development marks a significant milestone as Rovadicitinib progresses through Phase III clinical trials in China and Phase II trials in the U.S., showcasing promising results in earlier trials with high response and survival rates. The company aims to expedite global R&D efforts to provide better treatment solutions for patients worldwide.

Sino Biopharmaceutical’s TQC3302 Receives Clinical Trial Approval

Sino Biopharmaceutical Limited announced that its new drug, TQC3302, a triple-combination soft mist inhalation formulation for chronic obstructive pulmonary disease (COPD), has received clinical trial approval from China’s National Medical Products Administration. This development marks a significant step in the company’s efforts to provide advanced treatment options for COPD patients, as no similar formulation has been approved globally, potentially enhancing the company’s market position and offering new opportunities for stakeholders.

Sino Biopharmaceutical Schedules Board Meeting for Interim Results and Dividend Consideration

Sino Biopharmaceutical Limited has announced a board meeting scheduled for August 18, 2025, to approve the publication of its unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting could impact the company’s financial strategy and shareholder returns, reflecting its ongoing operational and financial planning.

Sino Biopharmaceutical to Receive $300 Million Milestone Payment from Merck Collaboration

Sino Biopharmaceutical Limited announced that its subsidiary, LaNova Medicines, is progressing smoothly with its out-licensing collaboration with Merck & Co., Inc. for the LM-299/MK-2010 PD-1/VEGF Bispecific Antibody. The company is set to receive a US$300 million milestone payment following the successful technology transfer. This collaboration, which grants Merck exclusive global rights for LM-299, includes an upfront payment of US$588 million and potential milestone payments up to US$2.7 billion, highlighting Sino Biopharmaceutical’s strategic positioning in the global pharmaceutical market.

Sino Biopharmaceutical Gains FDA Approval for Innovative Cancer Drug

Sino Biopharmaceutical Limited announced that its subsidiary, LaNova Medicines, has received IND approval from the US FDA for LM-350, an innovative ADC targeting CDH17. This drug shows promise in treating various gastrointestinal tumors, particularly colorectal cancer, and highlights the company’s strong pipeline of ADC products in clinical and preclinical stages, potentially enhancing its industry positioning.

Sino Biopharmaceutical Expands with LaNova Medicines Acquisition Update

Sino Biopharmaceutical Limited has announced a supplemental update regarding its full acquisition of LaNova Medicines. The update includes additional information about the vendors involved in the transaction, such as QM162, Shanghai Jialang, and Summer Starry, which are backed by various venture capital and investment firms. The announcement also provides updated financial information for LaNova Medicines, reflecting the company’s ongoing efforts to strengthen its position in the healthcare industry through strategic acquisitions.

Sino Biopharmaceutical Advances TQB6411 in Phase I Clinical Trials

Sino Biopharmaceutical Limited has announced the successful first dosing of its self-developed Class 1 innovative drug, TQB6411, in a Phase I clinical trial in China. TQB6411 is a bispecific ADC targeting EGFR/c-Met, showing potential in treating various tumors such as non-small cell lung cancer and colorectal cancer. The drug has completed preclinical evaluations, demonstrating a clear anti-tumor mechanism and manageable toxicity risks. This development places Sino Biopharmaceutical among the leading global cohort in ADC drug development, with several other ADC projects in various stages of clinical trials.

Sino Biopharmaceutical Acquires Full Stake in LaNova Medicines

Sino Biopharmaceutical announced the full acquisition of LaNova Medicines, increasing its equity stake from 4.91% to 100%, making LaNova an indirect wholly-owned subsidiary. The acquisition, valued at up to USD950.92 million, is a discloseable transaction under Hong Kong’s Listing Rules, indicating a strategic expansion in the company’s operations and market positioning.

Sino Biopharmaceutical’s New Breast Cancer Treatment Gains Regulatory Acceptance

Sino Biopharmaceutical Limited has announced the acceptance of its new indication application for the marketing of Culmerciclib Capsule, a CDK2/4/6 inhibitor, in combination with fulvestrant injection for the first-line treatment of HR-positive, HER2-negative advanced breast cancer. This acceptance by the Centre for Drug Evaluation of the National Medical Products Administration of the PRC highlights the potential of this combination therapy in different stages of advanced breast cancer treatment, aligning with authoritative guidelines that recommend such therapies for this common subtype of breast cancer.

Sino Biopharmaceutical’s Anqixin® Approved for Marketing in China

Sino Biopharmaceutical Limited has announced the approval of its self-developed drug, Anqixin®, a recombinant human coagulation factor VIIa for injection, by the National Medical Products Administration of China. This approval marks the first domestically produced product of its kind in China, offering an economical and high-quality treatment option for hemophilia patients with inhibitors. The drug’s efficacy and safety were confirmed through a Phase III clinical trial, demonstrating a hemostatic efficacy rate of 88.93%. The company has developed proprietary processes for production, ensuring quality consistency across batches, and holds patents for its innovative methods. This development positions Sino Biopharmaceutical as a significant player in the hemophilia treatment market, potentially benefiting a broader population of patients.

Sino Biopharmaceutical’s Anlotinib Combo Approved for Soft Tissue Sarcoma

Sino Biopharmaceutical announced that its anlotinib hydrochloride capsules, combined with chemotherapy, have been approved by the National Medical Products Administration of China for first-line treatment of advanced or metastatic soft tissue sarcoma. This approval marks a significant milestone as it is the first combination therapy officially approved for this indication worldwide, showcasing the drug’s potential to improve treatment outcomes in a challenging cancer type. The approval is expected to enhance the company’s market positioning and provide new treatment options for patients, addressing unmet clinical needs in the field of soft tissue sarcoma.

Sino Biopharmaceutical’s LM-108 Gains Breakthrough Therapy Status in China

Sino Biopharmaceutical Limited announced that its jointly developed drug, LM-108, a CCR8 monoclonal antibody, has been included in China’s Breakthrough Therapy Designation process for treating advanced gastric/gastroesophageal junction adenocarcinoma. The drug has shown promising results in clinical trials, demonstrating significant efficacy in overcoming resistance to PD-1/PD-L1 inhibitors and offering new treatment options for patients who have failed previous therapies. LM-108 is the most advanced CCR8 monoclonal antibody globally and is expected to become a next-generation immunotherapy for various tumors, potentially impacting the company’s market positioning and providing new hope for patients.

Sino Biopharmaceutical Reports Breakthrough in GVHD Treatment with Rovadicitinib

Sino Biopharmaceutical Limited announced promising results from preclinical and Phase Ib clinical studies of rovadicitinib, a novel treatment for acute graft-versus-host disease (aGVHD), presented at the 2025 European Hematology Association Congress. The drug, a dual JAK/ROCK pathway inhibitor, showed an overall response rate of 84.6% at 28 days and a 12-month survival rate of 92.3%. These findings suggest rovadicitinib as a potential alternative for patients with steroid-refractory aGVHD, highlighting its rapid and sustained response and the ability to reduce steroid use. The company has also initiated a Phase III trial for chronic GVHD, reinforcing its commitment to advancing treatment options in this field.

Sino Biopharmaceutical’s TDI01 Gains Breakthrough Therapy Designation

Sino Biopharmaceutical Limited announced that its self-developed Class 1 innovative drug, TDI01 suspension, has been included in the Breakthrough Therapy Designation process by China’s Center for Drug Evaluation. TDI01, a ROCK2 inhibitor, has shown significant efficacy and safety in treating moderate to severe chronic graft-versus-host disease (cGVHD) and is also being trialed for other conditions like idiopathic pulmonary fibrosis. This advancement underscores the company’s commitment to providing innovative treatment options and may enhance its position in the pharmaceutical industry.

Sino Biopharmaceutical Advances Innovation-Driven Strategy with New Product Launches

Sino Biopharmaceutical Limited has announced significant progress in its innovation-driven development strategy, with a notable increase in revenue from innovative products and plans to launch several new products annually. The company is advancing multiple promising R&D pipelines, including drugs for chronic obstructive pulmonary disease, various cancers, and metabolic dysfunction-associated steatohepatitis, positioning itself as a leader in the biopharmaceutical industry.

Sino Biopharmaceutical Secures Shareholder Approval for Key Resolutions at AGM

Sino Biopharmaceutical Limited held its Annual General Meeting on June 10, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements for 2024, approval of a final dividend, re-election of directors, and authorization of the board to manage share capital and remuneration. The approval of these resolutions reflects strong shareholder support and positions the company for continued growth and stability in the biopharmaceutical sector.

Sino Biopharmaceutical Advances Phase III Study for Promising Pancreatic Cancer Drug

Sino Biopharmaceutical has received approval from the Center for Drug Evaluation of China to initiate a Phase III clinical study for its innovative drug, TQB2868 injection, aimed at treating metastatic pancreatic ductal adenocarcinoma (mPDAC). This drug, combined with anlotinib hydrochloride capsules and chemotherapy, has shown promising results in early trials, potentially becoming a groundbreaking first-line treatment option for pancreatic cancer, which currently has limited effective treatments and a low survival rate.

Sino Biopharmaceutical’s TQC3721 Receives Phase III Clinical Study Approval

Sino Biopharmaceutical has announced that its innovative drug, TQC3721 inhalation suspension, has received approval from China’s National Medical Products Administration to commence a phase III clinical study for COPD treatment. This drug, a PDE3/4 inhibitor, offers both bronchodilatory and anti-inflammatory effects, potentially improving treatment outcomes for COPD patients. The approval marks a significant step in the company’s research and development efforts, positioning it as a leader in COPD treatment innovation. The study will evaluate the drug’s efficacy and safety across a broader patient base, which could enhance its market positioning and provide a competitive edge in the global pharmaceutical industry.

Sino Biopharmaceutical’s Breakthrough in NSCLC Treatment at 2025 ASCO Meeting

Sino Biopharmaceutical has announced the results of its phase III clinical study for benmelstobart injection, with or without anlotinib, as a maintenance treatment for non-small cell lung cancer (NSCLC) at the 2025 ASCO Annual Meeting. The study demonstrated a significant extension in median progression-free survival for patients receiving the combination treatment, marking a potential shift in clinical practice guidelines and offering new hope for NSCLC patients. The study’s findings have led to the acceptance of a marketing application for the new indication by the National Medical Products Administration of China, highlighting the potential impact on the company’s operations and industry positioning.

Sino Biopharmaceutical’s Phase III Study Shows Promising Results for NSCLC Treatment

Sino Biopharmaceutical Limited announced the successful results of their phase III clinical study at the 2025 ASCO Annual Meeting, showcasing the efficacy of benmelstobart injection combined with anlotinib hydrochloride capsules as a first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC). The study, known as CAMPASS, demonstrated a significant improvement in progression-free survival (PFS) compared to pembrolizumab, with a notable 6.1-month prolongation in median PFS and a 40% reduction in the risk of disease progression or death in patients with TPS ≥50%. This advancement is expected to enhance first-line treatment options for PD-L1 positive advanced NSCLC patients in China, marking a significant clinical value in the oncology field.

Sino Biopharmaceutical’s TQB2868 Shows Promise in Pancreatic Cancer Treatment

Sino Biopharmaceutical Limited has announced promising preliminary results from a Phase II clinical study of its bi-functional fusion protein, TQB2868, combined with anlotinib and chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (mPDAC). The study, presented at the 2025 ASCO Annual Meeting, showed significant improvements in objective remission and disease control rates compared to traditional chemotherapy regimens, with a favorable safety profile. This development could mark a significant breakthrough in pancreatic cancer treatment, potentially positioning TQB2868 as the first immune checkpoint inhibitor for first-line treatment, thereby improving patient survival and quality of life.

Sino Biopharmaceutical Unveils Promising Phase I Data for TQB2102 at ASCO 2025

Sino Biopharmaceutical Limited has announced promising preliminary data from its phase I clinical study of TQB2102, a novel bispecific anti-HER2 antibody-drug conjugate, presented at the 2025 ASCO Annual Meeting. The study showed significant efficacy in treating various HER2-related cancers, including breast, colorectal, and gastric cancers, with a favorable safety profile compared to existing treatments. The ongoing phase III trials of TQB2102 are expected to potentially transform the treatment landscape for HER2 ADCs, offering a new therapeutic option with a lower incidence of adverse effects.

Sino Biopharmaceutical’s Breakthrough in Lung Cancer Treatment

Sino Biopharmaceutical has announced positive results from its Phase III clinical study of Benmelstobart Injection combined with chemotherapy and Anlotinib for treating advanced squamous non-small cell lung cancer (sq-NSCLC). The study, presented at the 2025 ASCO Annual Meeting, showed a significant improvement in median progression-free survival and overall response rates compared to the control group. This breakthrough could potentially change the treatment landscape for sq-NSCLC, offering new hope for patients with limited options.